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Summary
 
Inoculation of macaques with live attenuated SIV strains has been shown to protect against
subsequent challenge with wild-type SIV. The protective mechanism(s) remain obscure. To
study the effect in more detail, we have investigated the role of virus-specific CTL responses in
macaques infected with an attenuated SIV strain (pC8), which has a four–amino acid deletion
in the 
 
nef
 
 gene, as compared with the wild-type SIVmac32H clone (pJ5). Cynomolgus
macaques infected with pC8 were protected against subsequent challenge with pJ5 and did not
develop any AIDS-like symptoms in the 12 months after infection. The pC8-induced protec-
tion was associated with high levels of virus-specific CTL responses to a variety of viral anti-
gens. In contrast, pJ5-infected macaques had little, if any, detectable CTL response to the viral
proteins after three months. The latter group of macaques also showed increased Fas expression
and apoptotic cell death in both the CD4
 
1
 
 and CD8
 
1
 
 populations. In vitro, pJ5 but not pC8
leads to an increase in FasL expression on infected cells. Thus the expression of FasL may pro-
tect infected cells from CTL attack, killing viral-specific CTLs in the process, and providing a
route for escaping the immune response, leading to the increased pathogenicity of pJ5. pC8, on
the other hand does not induce FasL expression, allowing the development of a protective
CTL response. Furthermore, interruption of the Fas-FasL interaction allows the regeneration
of viral-specific CTL responses in pJ5-infected animals. This observation suggests an additional
therapeutic approach to the treatment of AIDS.
 
L
 
ive attenuated SIV
 
1
 
 or HIV with a deletion of the 
 
nef
 
gene exhibits reduced pathogenicity and does not
cause an AIDS-like illness (1–3). Moreover, macaques im-
munized with the 
 
nef
 
-mutant SIV are protected against su-
perinfection with wild-type pathogenic SIV (2, 4). How-
ever, the mechanism(s) of protection induced by the attenuated
virus are not known.
Accumulated evidence suggests that CTL play a critical
role in controlling HIV replication (5). HIV-specific CTL
activity has been observed at different stages of the disease
in infected individuals. In particular, the early induction of
an HIV-specific CTL response has been associated with the
initial control of viremia and may influence the subsequent
clinical outcome (6–8). However during disease progres-
sion the fall in CD4
 
1
 
 T cells is associated with a decrease in
CD8
 
1
 
 T cell numbers and an associated reduction in the
virus-specific CTL activity (9–11). Although several mech-
anisms are known to cause depletion of CD4
 
1
 
 T cells in
HIV infection (12–15), less is known about the mecha-
nisms leading to the fall in numbers and dysfunction of
CD8
 
1
 
 T cells, which probably result from several factors in
addition to the reduction of CD4
 
1
 
 T cell help. In particu-
lar, HIV-associated programmed cell death (apoptosis) has
been well documented in infected individuals (16–18). In-
 
1
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Induction of FasL in SIV Infection
 
terestingly, these apoptotic cells include not only unin-
fected CD4
 
1
 
 cells but also CD8
 
1
 
 (bystander) cells (18, 19).
Apoptosis of lymphocytes can be triggered by several cell
surface receptors including TNF-R1, Fas, and a newly
cloned molecule WSL-1/DR3 (20, 21). Each of these mol-
ecules will trigger apoptosis when it contacts its counter-
receptor or ligand, TNF and FasL for TNF-R1 and Fas, re-
spectively (22). Interaction between Fas and FasL plays a
important role in the homeostatic regulation of normal im-
mune responses (23). The expression of Fas is quite diffuse
being found on a variety of extra-lymphoid tissues such as
liver, ovary, and heart. The expression of FasL on the other
hand is much more tightly controlled being restricted to
activated lymphocytes and selected sites enjoying immune
privilege (24, 25).
Fas is upregulated on both CD4
 
1
 
 and CD8
 
1
 
 cells from
HIV-infected individuals (26, 27). However Fas expression
per se does not lead to cell death as ligation of Fas by FasL
is required to trigger apoptosis. There are therefore two
crucial questions relating to the death of CD8
 
1
 
 cells in
HIV infection, first where is FasL expressed, and secondly
what induces its expression.
To address this question, we have investigated CTL re-
sponses and apoptosis in macaques infected with the attenu-
ated SIV strain pC8 compared with the pathogenic wild-type
pJ5. Our results indicate that the mechanisms of protection
induced by the 
 
nef
 
-mutant SIV involves the induction of a
viral-specific CTL response. The failure of pC8-infected
CD4
 
1
 
 cells to upregulate FasL expression may allow the gen-
eration of an efficient antiviral response. In contrast the pJ5-
infected CD4
 
1
 
 
 
cells upregulate FasL expression which can
induce death of SIV-specific lymphocytes, including CTL
expressing Fas. This results in a failure to check viral repli-
cation and a consequent progression to AIDS.
 
Materials and Methods
 
Antibodies, Fusion Protein, and Cells
 
Antibodies.
 
Anti-human Fas monoclonal IgM was obtained
from UBI (Lake Placid, New York); anti-human Fas ligand mon-
oclonal antibodies, 4A5 and 4H9, were described previously (28).
Biotin-conjugated anti-human FasL mAb (NOK1) was purchased
from PharMingen (San Diego, CA). mAbs to SIV-
 
nef
 
 or 
 
env
 
 pro-
tein were made by NIBSC (London, UK). PE-conjugated anti-
CD4 and CD8 mAbs were purchased from Beckton Dickinson
(Mountain View, CA) and Dako Corp. (Carpinteria, CA), re-
spectively.
 
Fas–Fc Fusion Protein.
 
PCR primers F Fas Kpn AAT GCG
GTA CCT AGA TTA TCG TCC AAA AGT GTT AAT GCC
C and R Fas Bcl GCA CTT TGA TCA GAT CTG GAT CCT
TCC TCT TTG CAC TT were used to amplify sequences en-
coding the extracellular region of the Fas protein from PHA
blasted PBMC cDNA. After digestion with the appropriate re-
striction enzymes the fragment was cloned into a CMV driven
expression vector forming a fusion with the Fc region of human
IgG1. The plasmid DNA was then used for transient transfection
of COS cells by DEAE dextran (29). 4–5 d after transfection the
Fas–Fc fusion protein was passed over a protein A–Sepharose col-
umn and eluded with 0.1 M citric acid (pH 3.0).
 
Cells.
 
CEM or Jurkat CD4
 
1
 
 
 
T-lymphoblastoid cell lines were
obtained from the American Type Culture Collection (Gaithers-
burg, MD). Macaque PBMCs were isolated on Ficoll-Hypaque
and cultured in a R10H medium (RPMI containing 10% human
AB serum) as indicated.
 
Infection of Macaques or T Lymphocytes with SIVmac 
32H Clones
 
Two SIVmac 32H clones, pC8 and pJ5, were originally iso-
lated from rhesus macaque 32H inoculated with a SIVmac251 vi-
rus pool (1). The pC8 clone differs from the pJ5 clone by a four–
amino acid deletion in the 
 
nef
 
 open reading frame and expresses
an attenuated phenotype in vivo (4). Four cynomolgus macaques
were infected intravenously with pC8 (10
 
4
 
 TCID
 
50
 
) for 12 mo
and then challenged with a pathogenic SIVmac32H clone, pJ5
(50 MID
 
50
 
) for an additional 3 mo. Another group of four naive
macaques was infected with pJ5 (50 MID
 
50
 
) only.
In vitro infection of PBMCs or CEM cells. PBMC (1
 
 3 
 
10
 
6
 
)
were stimulated with Con A (5 
 
m
 
g/ml) for 12 h and superin-
fected with 200 
 
m
 
l of pC8 or pJ5 supernatant containing 5
 
 3 
 
10
 
4
 
TCID50 for 2 h at 37
 
8
 
C under 5% CO
 
2
 
. After washing three
times with RPMI 1640, cells were adjusted to a concentration of
2.0 
 
3 
 
10
 
5
 
/ml and incubated in R10H medium for another 48 h.
For infection of CEM cells, 1
 
 3 
 
10
 
6
 
 cells were infected with
400 
 
m
 
l of pC8 or pJ5 supernatant containing 5
 
 3 
 
10
 
4
 
 TCID50
for 2 h and incubated in R10H for another 24 h. Mock infection
was performed under the same conditions using a supernatant
generated from Con A–stimulated or unstimulated uninfected cells.
Infectivity of SIV was analyzed by staining intracytoplasmic 
 
nef
 
 ex-
pression or cell surface env expression using flow cytometry.
 
Detection of Virus Infection in Macaques
 
The presence of SIV-specific DNA sequences in the blood of
SIV challenged macaques was performed as described previously
(4). In brief, this involves the amplification of a region of the SIV
 
nef
 
 gene. Restriction analyses of PCR products using the enzyme
Rsa I allows the differentiation of products derived from pJ5 or
pC8 virus.
 
Detection of Virus-specific CTL Activities
 
SIV-specific CTL activity was measured in bulk cultures as
previously described (30). In brief, PBMC were isolated on Fi-
coll-Hypaque and one-tenth of the autologous PBMC were
stimulated with Con A (5 
 
m
 
g/ml) for 24 h. Cells were infected
with 100 
 
m
 
l SIV pC8 supernatant for 2 h, washed and then added
back to the remaining cells. Infected cells were then cultured in
R10H medium for 3 d and maintained for another 7–14 d in me-
dium supplemented with 10 U/ml IL-2. H. papio-transformed
autologous B cell lines infected with recombinant vaccinia viruses
carrying the SIV mac 
 
nef, gag/pol, env, RT, rev, tat,
 
 or control (in-
fluenza NP) gene were used as target cells. In some experiments
soluble Fas–Fc fusion protein (5 
 
m
 
g/ml) was added initially in
bulk cultures and the cells were then washed before using as ef-
fector cells in CTL assay. Cytotoxicity was determined by cultur-
ing 
 
51
 
Cr-labeled target cells with effector cells at various E/T ra-
tios for 4 h in 96-well U-bottomed plates. Maximum and
spontaneous release were determined by incubating target cells
with 5% Triton X-100 or media, respectively. Percentage lysis
was calculated as ([experimental release 
 
2 
 
spontaneous release]/
[maximum release 
 
2 
 
spontaneous release]) 
 
3 
 
100. Spontaneous
release varied from 10% to 25%. Specific lysis was calculated by 
9
 
Xu et al.
subtracting background killing of influenza NP-infected target
cells.
 
Detection of Apoptotic cells by DNA Fragmentation
 
PBMC were cultured in R10H media for 4 or 16 h and frag-
mented DNA was extracted according to the method previously
described (31). In brief, pelleted cells (0.5–1
 
 3 
 
10
 
6
 
 cells) were lysed
with 100 
 
m
 
l lysis buffer (1% NP-40, 20 mM EDTA, 50 mM Tris-
HCL, pH 7.5) for 1 min and centrifuged at 1,600 
 
g
 
 for 5 min.
The supernatant was collected and treated with 1% SDS and
RNAseA (5 
 
m
 
g/ml) at 56
 
8
 
C for 2 h. After digestion with pro-
teinase K (2.5 
 
m
 
g/ml) for 2 h at 37
 
8
 
C, the DNA was precipitated
by adding 1/2 volume of 10 M ammonium acetate and 2.5 vol of
cold ethanol, and then analyzed by electrophoresis on 1.5% aga-
rose gels. To quantitate the percentage DNA fragmentations
Southern blot was hybridized with 
 
32
 
P-labeled probe generated
by random priming of whole monkey genomic DNA. The per-
centage DNA fragmentation was calculated by dividing the total
counts by the counts found on DNA fragments below 23,000 bp
(32). DNA extracted from naive controls had 
 
,
 
20% of the
counts as determined by this method.
 
Flow Cytometry
 
For analysis of Fas expression, PBMCs (5
 
 3 
 
10
 
5
 
 ) were incu-
bated first with anti-Fas IgM monoclonal antibody and then with
a secondary FITC-conjugated rabbit anti–mouse IgM (Sigma Chem.
Co., St. Louis, MO). Fas stained cells were then counterstained with
a PE-conjugated anti-CD4 or CD8 mAbs. For intracytoplasmic
staining of SIV 
 
nef
 
 antigen, the infected cells were incubated with
the anti-SIV 
 
nef
 
 mAb together with 0.3% saponin (Sigma) and
then stained with a secondary FITC-conjugated rabbit anti–
mouse Ig (Sigma). Labeled cells were analyzed on a FACScan
 
Ò
 
.
Isotype-specific mAbs of irrelevant specificity were used as nega-
tive controls (Dako Corp.).
 
Analysis of FasL Expression
 
Functional FasL was assessed using a bioassay for FasL (33).
SIV-infected cells were cocultured with 
 
51
 
Cr-labeled Fas-sensi-
tive Jurkat cells at various E/T ratios in the presence or absence of
the human Fas–Fc fusion protein (10 
 
m
 
g/ml) or blocking anti-
FasL mAbs (5 
 
m
 
g/ml) for 12–16 h. The level of chromium release
into the supernatant was determined using a 
 
b
 
-plate counter.
To determine the level of FasL expression on the cell surface,
SIV-infected cells were incubated with 20 
 
m
 
l of biotin-conju-
gated anti-human FasL mAb (NOK-1; PharMingen), followed
by 5 
 
m
 
l of PE-conjugated streptavidin (Sigma). Negative controls
were either infected cells stained with PE-streptavidin only or unin-
fected cells stained with anti-FasL mAb and PE-streptavidin.
 
Results
 
Protective Effects of pC8 on Challenge of the Macaques with
pJ5.
 
After infection with the attenuated strain of SIV
pC8, all macaques became infected but did not develop the
characteristic clinical manifestations of AIDS over the sub-
sequent 12 mo. These pC8-infected macaques and four na-
ive animals were then challenged with pJ5. After 8 wk, the
viral load was assessed. The virus was recovered from all
naive animals after challenge but not from the animals that
had been preinfected with pC8 (Table 1), indicating that
the attenuated clone pC8 protects against subsequent chal-
lenge with pJ5.
 
Table 1.
 
Challenge with Wild-type SIV pJ5 in pC8-infected and Naive Macaques
 
Group
 
*
 
Before challenge After challenge
Abs to SIV
gp140
 
‡
 
Virus detected
by V/P
 
§
Abs to SIV
gp140
Virus detected
by V/P
pC8-infected
N113 4.0 2/? 4.0 2/pC8
N114 3.5 2/pC8 3.0 2/pC8
N115 3.6 2/pC8 3.6 2/?
N116 3.6 2/pC8 3.9 2/pC8
Naive
N174 ,1.5 2/ND 3.7 1/pJ5
N175 ,1.5 2/ND 3.5 1/pJ5
N176 ,1.5 2/ND 3.5 1/pJ5
N177 ,1.5 2/ND 3.3 1/pJ5
*Monkeys N113–116 were infected intravenously with 104 TCID50 of SIVpC8 for 35 mo and then together with naive N174–177 monkeys chal-
lenged intravenously with 50 MID50 SIV pJ5 clone.
‡Antibody to SIV gp140 was determined by ELISA using anti-SIV gp140 mAbs and data is end point titers expressed as log10.
§V, virus detected by virus isolation; P, virus detected by PCR. 1 indicates virus recovered from 5 3 106 PBMCs; 2 indicates no virus recovered
from 5 3 106 PBMCs; pC8 or pJ5 indicates PCR product with characterization of pC8 or pJ5 respectively; ? indicates indeterminate PCR product
unlike pJ5; ND indicates not determined.10 Induction of FasL in SIV Infection
SIV-specific CTL Activities. To investigate the mechanism
of protection induced by pC8, SIV-specific CTL responses
were measured in PBMC bulk cultures 3 mo after chal-
lenge with pJ5. All pC8-infected macaques showed multi-
ple virus-specific CTL responses to nef, gag/pol, env, RT,
rev, and/or tat, (Table 2). By contrast, no detectable virus-
specific CTL activity was observed in PBMC from pJ5-
infected animals, at an E/T of 30:1, although a weak CTL
response was found in a lymph node from one of these an-
imals.
Induction of Apoptosis In Vivo by SIV pJ5 Compared with
pC8. To characterize the loss of CTL responses in pJ5-
infected animals further, we analyzed the viability of PBMCs
in both groups. Freshly isolated PBMCs were cultured for 4
or 16 h in R10H medium at 378C and apoptosis was assessed
by DNA fragmentation (Fig. 1). Spontaneous apoptosis was
significantly higher in pJ5-infected macaques than in pC8-
infected animals after 16 h (47.2% vs. 18.1%, P ,0.001).
Apoptosis was more profound in the CD81 population
(CD4 vs. CD8: 28.3% vs. 41.4%, P ,0.05, respectively)
(Fig. 2). Thus T cells, in particular CD81 T cells, from pJ5-
infected animals are more vulnerable to apoptosis than
those from pC8-infected animals.
To explain this increased susceptibility to apoptosis we
analyzed Fas expression on lymphocyte subsets obtained
from pJ5 and pC8-infected animals (Fig. 3). Although Fas
expression was significantly increased in both infected
groups (pJ5: 36.9 6 12.7%, pC8: 17.6 6 4.2%) compared
with naive animals (6.2 6 1.2%), pJ5 induced a significantly
higher level of Fas expression than pC8 (P ,0.05) (Fig. 3
A). Moreover, while Fas expression was found to be up-
regulated on both CD41 and CD81 T cells in the pJ5
group, it was significantly higher in the CD81 T cells (P
,0.05).
Upregulation of Fas Ligand Expression on SIV-infected Cells.
Engagement of FasL is required for Fas-induced apoptosis,
so to search for the source of FasL we used a sensitive bio-
assay. The assay exploits the sensitivity of Jurkat cells to
Fas-mediated killing which can be blocked by the addition
of an excess of soluble Fas–Fc fusion protein or anti-FasL
mAbs.
PBMC or CEM cells were infected in vitro with either
pC8 or pJ5 and then cocultured with 51Cr-labeled Jurkat
cells (Fig. 4). The results for PBMC and CEM are equiva-
lent, and demonstrate that pJ5-infected but not pC8-
infected cells induce killing of Jurkat cells which is abro-
gated by Fas–Fc fusion protein, implying upregulation of
FasL in the pJ5-infected cells. To confirm the results of the
bioassay we analyzed FasL expression on infected CEM
cells, 24 h after infection, with an anti-FasL mAb. As ex-
pected FasL was upregulated in the pJ5 infected cells to a
greater degree than cells infected with pC8 (Fig. 5 A).
This phenomenon does not result from a difference in
the infectivity of the two viral strains. The percentage of
infected cells at 3 d, pC8 (98.3%; 76.5 MFI) and pJ5
(98.1%; 78.8 MFI), are equivalent when assessed with anti-
nef (Fig. 5 B). A similar result was obtained with anti-env
mAb (data not shown). Moreover, the lysis of Jurkat cells is
not due to direct viral invasion as Jurkat cells are resistant to
SIV infection (our unpublished observation and others
[34]). Similar results were also made with fresh PBMC iso-
lated from macaques 3 mo after infection with pJ5 (Fig. 6).
Fractionation of T cells from these macaques demonstrates
that although the CD81 population expresses more Fas, the
Table 2. SIV-specific CTL Responses after SIVpJ5 Challenge in pC8-infected and Naive Macaques
Target cell
infection‡
SIV pJ5 challenge on* (% specific lysis at E/T 5 30:1)
pC8-infected Naive
N113 N114 N115 N116 N174 N175 N177
rVV-nef 7.2§ ,1.0 19.3 19.4 ,1.0 ,1.0 ,1.0
(3.9)i (7.4)i
rVV-gag/pol ,1.0 11.8 ,1.0 17.8 2.0 ,1.0 ,1.0
(2.4)i (11.2)i
rVV-env 22.9 ,1.0 12.5 16.6 ,1.0 ,1.0 ,1.0
(9.1)i
rVV-RT ,1.0 ,1.0 ,1.0 25.5 ,1.0 ,1.0 ,1.0
rVV-rev ,1.0 18.7 13.6 ,1.0 ,1.0 ,1.0 ,1.0
rVV-tat ,1.0 31.5 ,1.0 9.1 ,1.0 ,1.0 ,1.0
*pC8-infected (N113–N116) or naive (N14, N175, and N177) macaques were intravenously injected with 50 MID50 SIV pJ5 clone as shown in Ta-
ble 1 and bulk cultured CTL activities were determined at 3 mo after infection.
‡Herpes papio-transformed autologous B cell lines were infected with recombinant vaccinia viruses (10 PFU/cell) expressing SIV proteins for 2 h at
378C. After washing the cells were cultured in RPMI 10% FCS for 12 h and then used as target cells.
§Specific lysis was calculated by subtracting the background killing of rVV fluNP-infected target.
iCTL activities in lymph nodes.11 Xu et al.
majority of FasL activity resides in the CD41 population,
probably on SIV-infected cells.
CTL Responses Can Be Restored by Blocking Fas–FasL In-
teractions. One explanation for the poor CTL responses
mounted by the pJ5-infected macaques is that SIV-infected
CD41 cells, which we have demonstrated to express FasL,
paradoxically kill cognate cytotoxic T cells. If this is the
case we should be able to restore CTL responses by block-
ing the interaction of FasL expressed on infected CD41
T cells with Fas expressed on CTL.
We tested this hypothesis with a bulk culture CTL assay
in the presence or absence of Fas–Fc fusion protein. No
CTL responses were elicited from cells cultured with me-
dium alone or soluble CD4 protein, in agreement with our
previous results on the pJ5-infected macaques. However,
in the presence of soluble Fas–Fc fusion protein a nef-spe-
cific CTL response was established (Fig. 7).
Discussion
Loss of functional immune cells is a hallmark of AIDS.
This was initially thought to result from direct viral cyto-
toxicity on CD41 T cells with a consequent loss of T cell
help (35). However, it is now clear that a considerable loss
of uninfected bystander lymphocytes occurs in HIV-infected
individuals. Much of this loss is due to apoptosis occurring
in both CD41 and CD81 T cells (18, 26, 32, 36). Why this
happens is not understood.
Figure 1. Spontaneous DNA fragmentation of PBMCs from pC8-
induced protected (N113-N114) or pJ5-infected (N174-N177) macaques.
Fresh isolated PBMCs (1 3 106) were cultured in medium containing
10% human AB serum for 4 or 16 h. Fragmented DNA was extracted as
described in Materials and Methods. (A) DNA was analyzed by electro-
phoresis on 1.5% agarose gels; (B) Southern blot analysis of the DNA by
hybridization with 32P-labeled genomic macaque DNA; (C) The percent-
age of DNA fragmentation in B was calculated as dividing the total counts
of each sample by the number of counts in the bottom 85–90% of the gel
(below 23,000 bp). The percentage of DNA fragmentation of PBMCs
from naive macaques was always ,20% (data not shown). P value for the
two groups ,0.005 after 16 h.
Figure 2. Spontaneous DNA fragmentation of CD4 and CD8 subpop-
ulations from pJ5-infected control (N174-N177) macaques. PBMCs were
cultured in the medium for 16 h and CD41 or CD81 T cells was then
purified by positive selection using anti-CD4 or CD8 magnetic beads, re-
spectively. The purity of each subset was .95% as assessed by flow cy-
tometry. After extracting the DNA, Southern blot was performed (A) and
analyzed as described in Fig. 1 (B). P value for CD4 vs CD8 ,0.05.
These data are representative of three separate experiments.12 Induction of FasL in SIV Infection
To date, the most effective vaccination strategy in macaques
has been the use of live attenuated nef mutant SIV such as
pC8 (2, 4). Our results show that one possible contributing
mechanism to such protection is the induction of strong vi-
rus-specific CTL responses with multiple specificities. Some
CTL responses can be elicited from pJ5-infected macaques
within 8 wk of infection (37), but at 3 mo these appear to
be lost revealing a striking difference in the responses of the
animals to challenge with pC8 and pJ5. In addition, the
strong CTL activity observed in the protected animals cor-
relates with a lower frequency of apoptotic cell death of
both CD41 and CD81 T cells. Fas, which is upregulated in
T cells from HIV1 patients is a candidate for the induction
of apoptosis seen in the uninfected cells (26, 32). Our study
in SIV corroborates these results showing increased expres-
sion of Fas in both CD41 and CD81 T cells. Interestingly,
animals infected with nef-attenuated SIV express less Fas
antigen on their cell surface. The mechanism by which un-
infected T cells overexpress Fas antigen is unknown, but
this may reflect the generalized state of immune activation
seen in SIV/HIV infection.
FasL expression is tightly regulated being confined to ac-
tivated lymphocytes, Sertoli cells, stromal cells of the ante-
rior chamber of the eye, and neurons (22). The expression
at these nonlymphoid sites of immune privilege suggests
that FasL may play a role in protection from immunologi-
cal attack (38). Indeed, it has recently been shown that allo-
geneic transplanted testes from gld mice that lack FasL ex-
pression are rapidly rejected (39). Tumor cells may also
express FasL, gaining immune privilege and escaping an
anti-tumor immune response (25, 40, 41). HIV has been
shown to upregulate FasL expression on macrophages (42)
Figure 3. Expression of Fas antigen on SIV-infected macaques. (A)
Representative histograms of Fas expression on PBMCs. The percentage
of Fas positive cells (mean fluorescent intensity .13 units): naive 6.2 6
1.2% (n 5 4), C81J5-infected 17.6 6 4.2% (n 5 4), or pJ5-infected 36.9 6
12.7% (n 5 4) macaques (C81J5 vs J5 P ,0.05). (B) Fas expression on
fractionated CD41 or CD81 T cells from pC8- and pJ5-infected groups
(P 5 0.08 for CD41 cells and P ,0.05 for the CD81 cells).
Figure 4. SIV-infected cells kill Fas-sensitive target via FasL–Fas inter-
action. Naive monkey PBMCs (A) or CEM cells (B) were superinfected
with SIV pC8 or pJ5 as indicated in Materials and Methods. SIV-infected
cells were cocultured with 51Cr-labeled Fas-sensitive Jurkat cells in the
presence or absence of Fas–Fc fusion proteins (10 mg/ml) for 12–16 h.
Chromium release was determined by a b-plate counter. Specific lysis was
calculated by subtracting the killing of Jurkat cells by mock-infected cells.
Infectivity of SIV pC8 or pJ5 in CEM cells.13 Xu et al.
and HIV tat/gp120 can enhance anti-CD3–induced apop-
tosis by increasing the expression of FasL on CD41 cells
(43). In our studies we have assessed the effects of FasL up-
regulation upon apoptosis and the course of infection in
vivo. We demonstrate that freshly isolated PBMC show in-
creased FasL expression and kill Fas-sensitive targets which
is blocked by soluble Fas–Fc fusion protein or anti-FasL
mAb. The activity of FasL is contained within the CD41
Figure 6. PBMCs from SIV pJ5-infected macaques kill Fas-sensitive
target are CD4-dependent. PBMCs from pJ5-infected or uninfected
macaques (n 5 2 in each group) were stimulated with Con A (5 mg/ml)
for 12 h. After washing three times with RPMI, CD41 or CD81 T cells
were depleted by using anti-CD4 or CD8 magnetic beads, respectively.
Cells were then cocultured with 51Cr-labeled Jurkat cells in the presence
or absence of fusion proteins (10 mg/ml) or anti-human FasL mAbs
(5  mg/ml) for 12–16 h. Specific lysis was assayed as described in Fig. 4.
Figure 5. (A) Comparison of FasL induction by infection with pC8 or
pJ5 as assessed by staining with the anti-FasL mAb. 24 h after infection
cells were stained with biotinylated anti-human FasL mAb (NOK-1) plus
PE-streptavidin (solid lines). Dotted lines indicate background staining
with PE-streptavidin alone. (B) Staining of infected cells (solid lines) with
anti-nef mAb demonstrates equal infectivity of pC8 and pJ5 infection.
Dotted lines indicate background staining with control mAb.14 Induction of FasL in SIV Infection
population, possibly SIV-infected cells. Our demonstration
at the protein level of FasL induction by SIV infection is
consistent with the demonstration of FasL induction on
HIV-infected CD41 cells shown by RT-PCR (44). On
the other hand, nef mutant SIV-infected cells do not upreg-
ulate FasL expression. The nef gene codes for a protein that
is not essential for viral growth in vitro, but which is essen-
tial to the development of AIDS (45). Nef leads to the
downregulation of CD4 expression and is believed to in-
crease the state of T cell activation through interactions
with proteins involved in cellular activation and signaling
such as Src family tyrosine kinases (46). T cell activation via
several modalities leads to an increase in FasL expression
(33), so nef through enhancing T cell activation may simi-
larly lead to the expression of FasL. The mechanisms un-
derlying the failure of the nef-mutant SIV pC8 to induce
FasL expression require clarification. In preliminary experi-
ments, we have shown that full-length nef expression by
vaccinia does not upregulate FasL. This may be due to ei-
ther counter-activity induced by vaccinia gene products or
other HIV/SIV genes may be involved.
We propose that the increased expression of FasL is the
cause for the increased pathogenicity of wild-type SIV pJ5.
The FasL expression by infected CD41 cells can trigger apop-
tosis of virus-specific CTL, which themselves express Fas.
This situation thus mimics the expression of FasL at sites of
immune privilege, or the upregulation of FasL by certain
tumors. In this way the virus can evade the immune re-
sponse by preventing the development of an effective CTL
response. The effective CTL response developed by macaques
infected with pC8, which does not cause FasL expression
in CD41 cells, suggests that inhibition of the FasL activity
on infected cells may restore CTL responses. This is indeed
the case; our results show that incubation of cells from the
infected macaque with soluble Fas leads to the generation
of an efficient anti-nef CTL response. These results suggest
a new therapeutic intervention in the treatment of SIV/HIV
which we are testing on infected macaques in vivo.
Figure 7. Soluble Fas–Fc fusion protein regenerates CTL response
from SIV pJ5-infected macaques. PBMCs were isolated from macaques
(P93) 6 mo after infection and set up for bulk culture CTL in the pres-
ence or absence of either Fas–Fc fusion protein (10 mg/ml) or soluble
CD4 (5 mg/ml) for 14 d. After washing the cells, the virus-specific CTL
activities were determined as described in Materials and Methods. The
data are representative of three seperate experiments.
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